Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J GRIGNON

Showing results (221-230 of 251) with videos related to

Pageof 26
Sort By:
The American Journal of Surgical Pathology|February 9, 2021
Distal Tubular Hyperplasia: A Proposal for a Unique Form of Renal Tubular Proliferation Distinct From Papillary AdenomaSean R Williamson, Khaleel I Al-Obaidy, Liang Cheng, et al.
International Journal of Radiation Oncology, Biology, Physics|January 28, 2017
Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202Amin J Mirhadi, Qiang Zhang, Gerald E Hanks, et al.
Human Pathology|April 15, 2015
Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFRNovae B Simper, Carol L Jones, Gregory T MacLennan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2019
Molecular Biomarkers in Localized Prostate Cancer: ASCO GuidelineScott E Eggener, R Bryan Rumble, Andrew J Armstrong, et al.
Archives of Pathology & Laboratory Medicine|July 11, 2000
Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999D G Bostwick, D J Grignon, M E Hammond, et al.
Journal of the National Cancer Institute|January 15, 1997
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610D J Grignon, R Caplan, F H Sarkar, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 26, 2013
Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markersQiu Rao, Sean R Williamson, Antonio Lopez-Beltran, et al.
Histopathology|August 28, 2015
Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinomaThu Tran, Carol L Jones, Sean R Williamson, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 8, 2015
Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastomaStephanie N Kinney, John N Eble, Ondrej Hes, et al.
Histopathology|November 20, 2014
Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in-situ hybridization for the detection of anaplastic lymphoma kinase alterationsEuna Choi, Sean R Williamson, Rodolfo Montironi, et al.
Pageof 26

Showing results (221-230 of 251) with videos related to

Sort By:
Pageof 26
The American Journal of Surgical Pathology|February 9, 2021
Distal Tubular Hyperplasia: A Proposal for a Unique Form of Renal Tubular Proliferation Distinct From Papillary AdenomaSean R Williamson, Khaleel I Al-Obaidy, Liang Cheng, et al.
International Journal of Radiation Oncology, Biology, Physics|January 28, 2017
Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202Amin J Mirhadi, Qiang Zhang, Gerald E Hanks, et al.
Human Pathology|April 15, 2015
Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFRNovae B Simper, Carol L Jones, Gregory T MacLennan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2019
Molecular Biomarkers in Localized Prostate Cancer: ASCO GuidelineScott E Eggener, R Bryan Rumble, Andrew J Armstrong, et al.
Archives of Pathology & Laboratory Medicine|July 11, 2000
Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999D G Bostwick, D J Grignon, M E Hammond, et al.
Journal of the National Cancer Institute|January 15, 1997
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610D J Grignon, R Caplan, F H Sarkar, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 26, 2013
Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markersQiu Rao, Sean R Williamson, Antonio Lopez-Beltran, et al.
Histopathology|August 28, 2015
Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinomaThu Tran, Carol L Jones, Sean R Williamson, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 8, 2015
Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastomaStephanie N Kinney, John N Eble, Ondrej Hes, et al.
Histopathology|November 20, 2014
Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in-situ hybridization for the detection of anaplastic lymphoma kinase alterationsEuna Choi, Sean R Williamson, Rodolfo Montironi, et al.
Pageof 26